600196 复星医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)5.2965.9605.2878.90612.413
总资产报酬率 ROA (%)2.1422.3992.1633.7225.343
投入资产回报率 ROIC (%)2.7233.0562.7584.8446.946

边际利润分析
销售毛利率 (%)48.20147.97447.83747.28448.144
营业利润率 (%)13.29110.3377.98910.59516.156
息税前利润/营业总收入 (%)16.05912.85610.26311.88116.679
净利润/营业总收入 (%)10.3978.5536.9938.98112.756

收益指标分析
经营活动净收益/利润总额(%)25.48140.0473.53756.95431.740
价值变动净收益/利润总额(%)70.88947.69894.18141.08782.350
营业外收支净额/利润总额(%)-1.809-1.819-1.315-1.799-4.301

偿债能力分析
流动比率 (X)0.9160.9211.0011.0591.038
速动比率 (X)0.7210.7270.7780.8530.851
资产负债率 (%)48.51748.97550.10449.50848.150
带息债务/全部投入资本 (%)36.65137.96038.27337.44735.137
股东权益/带息债务 (%)139.945135.770133.295142.559158.135
股东权益/负债合计 (%)83.80682.15580.35584.03187.243
利息保障倍数 (X)5.3464.7544.3178.06614.022

营运能力分析
应收账款周转天数 (天)74.16768.35766.22655.77148.883
存货周转天数 (天)124.966124.656120.19495.98394.631